Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2010 | Original Article

Individualized dosimetry in patients undergoing therapy with ¹⁷⁷Lu-DOTA-D-Phe¹-Tyr³-octreotate

Authors: Mattias Sandström, Ulrike Garske, Dan Granberg, Anders Sundin, Hans Lundqvist

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2010

Abstract

Purpose

In recent years, targeted radionuclide therapy with [¹⁷⁷Lu-DOTA⁰, Tyr³]octreotate for neuroendocrine tumours has yielded promising results. This therapy may be further improved by using individualized dosimetry allowing optimization of the absorbed dose to the tumours and the normal organs. The aim of this study was to investigate the feasibility and reliability of individualized dosimetry based on SPECT in comparison to conventional planar imaging.

Methods

Attenuation-corrected SPECT data were analysed both by using organ-based volumes of interest (VOIs) to obtain the total radioactivity in the organ, and by using small VOIs to measure the tissue radioactivity concentration. During the first treatment session in 24 patients, imaging was performed 1, 24, 96 and 168 h after [¹⁷⁷Lu-DOTA⁰, Tyr³]octreotate infusion. Absorbed doses in non tumour-affected kidney, liver and spleen were calculated and compared for all three methods (planar imaging, SPECT organ VOIs, SPECT small VOIs).

Results

Planar and SPECT dosimetry were comparable in areas free of tumours, but due to overlap the planar dosimetry highly overestimated the absorbed dose in organs with tumours. Furthermore, SPECT dosimetry based on small VOIs proved to be more reliable than whole-organ dosimetry.

Conclusion

We conclude that SPECT dosimetry based on small VOIs is feasible and more accurate than conventional planar dosimetry, and thus may contribute towards optimising targeted radionuclide therapy.

Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148–55.CrossRefPubMed

Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1038–46.CrossRefPubMed

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62S–6.PubMed

Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–62.CrossRefPubMed

Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147–56.CrossRefPubMed

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy and survival. J Clin Oncol 2008;26:2124–30.CrossRefPubMed

Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37:847–51.CrossRefPubMed

Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001;28:1552–4.CrossRefPubMed

Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001;28:1319–25.CrossRefPubMed

10.

Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467–75.PubMed

11.

Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 2007;22:406–16.CrossRefPubMed

12.

Stabin M. Fundamentals of nuclear medicine dosimetry. Springer. 2008; ISBN 978-0-387-74578-7.

13.

Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46 (Suppl 1):99S–106S.PubMed

14.

Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 2007;48:134–42.PubMed

15.

Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. Clin Radiol 2008;63(3):241–51.CrossRefPubMed

16.

Ljungberg M, Frey E, Sjogreen K, Liu X, Dewaraja Y, Strand SE. 3D absorbed dose calculations based on SPECT: evaluation for 111In/90Y therapy using Monte Carlo simulations. Cancer Biother Radiopharm 2003;18:99–107.CrossRefPubMed

17.

Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2009;36:e-pub ahead of print.

18.

Flemming JS. A technique for absolute measurement of activity using a gamma camera and computer. Phys Med Biol 1979;24:176–80.CrossRef

19.

Leide-Svegborn S. Radiation exposure of the patient in nuclear medicine. Experimental studies of the biokinetics of 111In-DTPA-D-Phe1-octreotide, 99mTc-MIBI, 14C-triolein and 14C-urea and development of dosimetric models. Dissertation: Lund University, 1999.

20.

ICRP. ICRP Publication 23. Reference man: anatomical, physiological and metabolic characteristics. Elsevier; 1975.

21.

Stabin M, Siegel J, Lipsztein J, et al. RADAR (RAdiation Dose Assessment Resource). http://www.doseinfo-radar.com/RADARphan.html. Accessed 14 July 2009.

22.

Williams LE, DeNardo GL, Meredith RF. Targeted radionuclide therapy. Med Phys 2008;35:3062–8.CrossRefPubMed

23.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–7.PubMed

24.

Bernhardt P, Ahlman H, Forssell-Aronsson E. Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentration. Med Phys 2004;31:2628–35.CrossRefPubMed

25.

Valkema R, Pauwels S, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med 2005;46:83S–91.PubMed

Title: Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
Authors: Mattias Sandström
Ulrike Garske
Dan Granberg
Anders Sundin
Hans Lundqvist
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1216-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Individualized dosimetry in patients undergoing therapy with ¹⁷⁷Lu-DOTA-D-Phe¹-Tyr³-octreotate

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2010

No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer

Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium

Molecular imaging in cognitive impairment: the relevance of cognitive reserve, importance of multisite longitudinal trials and challenges of standardised analysis

Unsuspected hibernating myocardium detected by routine oncology 18F-FDG PET/CT

Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy

Radiobiological effects of hypoxia-dependent uptake of 64Cu-ATSM: enhanced DNA damage and cytotoxicity in hypoxic cells